Journal: Drug Invention Today

Article Id: JPRS-Pcol-00004436
Title: A prospective randomized control study on effect of liraglutide on cardiovascular outcomes in type II diabetes mellitus
Category: Pharmacology
Section: Research Article
  • Abstract
  • Audio Abstract
  • Authors
  • Pdf File
  • Citation
  • My Reference
  • Methodology
  • Abstract

    Objective: The objective of the study was to evaluate the effect of liraglutide and cardiovascular outcomes in Type II diabetes mellitus (DM), to determine the role of liraglutide along with cardiovascular outcome in Type II DM, to determine the drug interactions in such a treatment regimen, and to evaluate the safety of the regimen. Methodology: Type II DM patients with or absence of complications were included in this study along with serum glycosylated hemoglobin (HbA1c) concentration between 7.5 and 9.5%. They are divided into test group, i.e., Group-B (which received liraglutide with metformin) and control group, i.e., Group-A received metformin with sitagliptin combination. Body mass index (BMI) status, fasting blood sugar (FBS), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) C-reactive protein and troponin T were noted at every 3 months of interval at total 6 months of this study. HbA1c percentage was measured at 3rd month after initiation of this study, patients with other comorbidities were found to be prominent in this study. Results: The principle message of our study is effect of liraglutide on cardiovascular outcome in Type II DM, as shown in result section, there was a significant decrease in FBS, HbA1c, BMI, C-reactive protein, troponin, LDL, and HDL, which was statistically significant at the end of 6 months of study, thus, concludes that liraglutide minimizes occurrence of cardiovascular disease in Type II DM. Conclusion: The principle message of our study is effect of liraglutide on cardiovascular outcome in Type II DM, as shown in result section, there was a significant decrease in FBS, HbA1c, BMI, C-reactive protein, troponin, LDL, and HDL, which was statistically significant at the end of 6 months of study, thus, concludes that liraglutide minimizes the chance of occurrence of cardiovascular disease in Type II DM.

  • Abstract Audio

    No Audio file found

  • About the authors and Affiliations

    Author(s) Name:

    D. Pavithra1 , D. Praveen2 , P. Ranadheer Chowdary2 , M. Vijey Aanandhi 3 *

    Affiliation(s) Name:

    1 Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India,

    2 Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India,

    3 Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, “Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India

    *Corresponding author: M. Vijey Aanandhi, Department of Pharmaceutical Chemistry and Analysis School of Pharmaceutical Sciences Vels Institute of Science, Technology and Advanced Studies, Pallavaram, Chennai - 600 117, Tamil Nadu, India.

  • View Article File in pdf format.

    Article File
  • View Article Citation Here.

    0 View More
  • How to Cite my Article.

    Author:

    D. Pavithra1 , D. Praveen2 , P. Ranadheer Chowdary2 , M. Vijey Aanandhi 3 *

    Title:A prospective randomized control study on effect of liraglutide on cardiovascular outcomes in type II diabetes mellitus
    Journal:Drug Invention Today
    Vol(issue):12 (November )
    Year:2019
    Page No: (2549-2552)
  • Experimental Methods Keywords

    Methodology:A prospective randomized control study
    Research Materials:Type II DM patients

Keywords

Cardiovascular outcomes Complications Diabetes mellitus Liraglutide

Our Services

Most Downloaded List